Adolescence

Medical Spa Global Market Report 2022: Rise in Demand for Aesthetic Procedures to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022 - 4:33pm

The "Medical Spa Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Spa Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the medical spa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The rise in demand for aesthetic procedures is expected to propel the growth of the medical spa market.
  • Thus, the rise in demand for aesthetic procedures will drive the medical spa market.

Global Human Papillomavirus Vaccine Market Forecast to 2028: Advancements in HPV Diagnostics Tests & Growing Number of HPV Awareness Programs - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022 - 11:39am

The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.

Key Points: 
  • The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028.
  • Based on type, the human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine.
  • The global human papillomavirus (HPV) vaccine market, based on age, is segmented into 9 to 14 years and 15 to 45 years.
  • In terms of application, the global human papillomavirus (HPV) vaccine market is segmented into HPV-attributable cancers and genital warts.

Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Retrieved on: 
Thursday, August 4, 2022 - 9:30pm

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the second quarter of 2022 and highlighted recent corporate achievements.

Key Points: 
  • Day One anticipates releasing topline results for the full FIREFLY-1 pivotal study population in the first quarter of 2023.
  • Day One expects to dose the first patient in FIREFLY-2/LOGGIC trial in the third quarter of 2022.
  • R&D Expenses: Research and development expenses were $22.6 million for the second quarter of 2022 compared to $9.9 million for the second quarter of 2021.
  • G&A Expenses: General and administrative expenses were $14.2 million for the second quarter of 2022 compared to $5.5 million for the second quarter of 2021.

electroCore Announces Record Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022 - 9:05pm

ROCKAWAY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced second quarter 2022 financial results and provided an operational update.

Key Points: 
  • Gross margin for the second quarter of 2022 was 83%, compared to 81%in the first quarter of 2022 and 71%in the second quarter of 2021.
  • Total operating expenses in the second quarter of 2022 were approximately $7.6 million as compared to $7.1 million in the first quarter of 2022 and $6.1 million in the second quarter of 2021.
  • Research and development expense in the second quarter of 2022 was $1.3 million as compared to $934,000 in the first quarter of 2022 and $825,000 in the second quarter of 2021.
  • Selling, general and administrative expense in the second quarter of 2022 was $6.3 million as compared to $6.2 million in the first quarter of 2022 and $5.3 million in the second quarter of 2021.

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Retrieved on: 
Thursday, August 4, 2022 - 1:00pm

Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.

Key Points: 
  • Orpheus is a multi-center, 11-week prospective, placebo-controlled study to evaluate the safety and efficacy of gemlapodect as monotherapy in adults suffering from COFD.
  • "Recruiting the first participant is an important step in the clinical investigation of gemlapodect in this indication.
  • "Our main goal is to evaluate the safety and efficacy of gemlapodect as a monotherapy for COFD in adults.
  • Gemlapodect, a PDE10A inhibitor, is currently enrolling a Phase 2a clinical trial in patients with Tourette Syndrome.

More countries sign on to use Children First Software to help end institutionalization of their children

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm

PLANO, Texas, Aug. 4, 2022 /PRNewswire/ -- Texas-based technology non-profit Both Ends Believing grows in 2022 as four new countries now partner to use Children First Software. BEB offers its software platform to governments at no cost and puts an expert team on the ground to facilitate implementation of, and training on, the software. The goal of CFS is to equip governments to create digital files for all their institutionalized children and move them to families. To date, over 30,000 children have profiles in the system – representing 273% growth in three years.

Key Points: 
  • BEB offers its software platform to governments at no cost and puts an expert team on the ground to facilitate implementation of, and training on, the software.
  • The goal of CFS is to equip governments to create digital files for all their institutionalized children and move them to families.
  • To date, over 30,000 children have profiles in the system representing 273% growth in three years.
  • BEB works to capture comprehensive digital profiles of children through Children First Software (CFS), a technology-driven advocate designed to identify a child's best opportunity for family-based care.

Tarena to Report Second Quarter 2022 Financial Results on Aug 16, 2022

Retrieved on: 
Wednesday, August 3, 2022 - 11:03am

BEIJING, Aug. 3, 2022 /PRNewswire/ -- Tarena International, Inc. (NASDAQ: TEDU)("Tarena" or the "Company"), a leading provider of adult professional education and childhood & adolescent quality education services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2022, before the U.S. market opens on August 16, 2022.

Key Points: 
  • BEIJING, Aug. 3, 2022 /PRNewswire/ -- Tarena International, Inc. (NASDAQ: TEDU)("Tarena" or the "Company"), a leading provider of adult professional education and childhood & adolescent quality education services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2022, before the U.S. market opens on August 16, 2022.
  • Tarena's management will host an earnings conference call and live webcast at 8:00 a.m. on Aug 16, 2022, U.S. Eastern Time (8:00 p.m. on Aug 16, 2022, Beijing Time).
  • It will automatically direct you to the registration page of "Tarena's Second Quarter 2022 Earnings Conference Call " where you may fill in your details for RSVP.
  • Tarena also offers childhood and adolescent quality education programs, including computer coding and robotics programming courses, etc., targeting students aged between three and eighteen.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

98% of schools will increase youth mental health spending in the upcoming academic year, according to new survey

Retrieved on: 
Tuesday, August 2, 2022 - 6:17pm

SAN FRANCISCO, Aug. 2, 2022 /PRNewswire/ -- A national emergency in youth mental health was declared at the end of last year by the U.S. Surgeon General, the American Academy of Pediatrics, the American Academy of Child and Adolescent Psychiatry, and the Children's Hospital Association. But the increased demand for mental health services combined with a lack of qualified mental health professionals, the cost of care, and the time it takes to find a clinician makes accessing care a challenge for most American families.

Key Points: 
  • A recent research study, " The State of Youth Mental Health & Our Schools ," commissioned by Daybreak Health , surveyed educators and parents in several dimensions related to the youth mental health crisis and schools.
  • In response to the youth mental health crisis, many school systems have either already increased or will be increasing their spending on mental health services.
  • Which is why a whopping 98% report that they plan to increase mental health spending in the upcoming academic year.
  • The top 3 services districts plan to invest most heavily include virtual mental health services, mental health screening, and mental health education.

Timberline Knolls Residential Treatment Center Now Offers Sound Therapy for Addiction, Trauma, and Mental Health Recovery

Retrieved on: 
Tuesday, August 2, 2022 - 4:11pm

Chicago, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Timberline Knolls Residential Treatment Center, a nationally recognized behavioral health facility serving women and adolescent girls, recently added sound therapy to its repertoire of expressive therapies, which the center uses to help clients heal from substance use disorders, trauma, and other mental health conditions.

Key Points: 
  • Chicago, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Timberline Knolls Residential Treatment Center, a nationally recognized behavioral health facility serving women and adolescent girls, recently added sound therapy to its repertoire of expressive therapies, which the center uses to help clients heal from substance use disorders, trauma, and other mental health conditions.
  • As Americas need for behavioral health treatment continues to grow, having additional approaches like sound therapy is more essential than ever.
  • Timberline Knolls has been at the forefront of the behavioral health industry by offering sound therapy as another way to support its clients.
  • Sound healing has been very well-received by our residents, said Elisabeth Nuesser, E-RYT, TIY, RCYT, trauma-informed yoga facilitator at Timberline Knolls.